PL3740190T3 - Postać krystaliczna cząstek stałych kokryształu apomorfina·kwas palmitynowy - Google Patents
Postać krystaliczna cząstek stałych kokryształu apomorfina·kwas palmitynowyInfo
- Publication number
- PL3740190T3 PL3740190T3 PL19700411.2T PL19700411T PL3740190T3 PL 3740190 T3 PL3740190 T3 PL 3740190T3 PL 19700411 T PL19700411 T PL 19700411T PL 3740190 T3 PL3740190 T3 PL 3740190T3
- Authority
- PL
- Poland
- Prior art keywords
- apomorphine
- palmitic acid
- crystal form
- acid cocrystal
- particulate crystal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Glass Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382023 | 2018-01-18 | ||
| PCT/EP2019/050922 WO2019141673A1 (en) | 2018-01-18 | 2019-01-15 | Apomorphine·palmitic acid cocrystal solid particle crystalline form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3740190T3 true PL3740190T3 (pl) | 2025-03-24 |
Family
ID=61168020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19700411.2T PL3740190T3 (pl) | 2018-01-18 | 2019-01-15 | Postać krystaliczna cząstek stałych kokryształu apomorfina·kwas palmitynowy |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11382867B2 (pl) |
| EP (2) | EP4509187A3 (pl) |
| JP (1) | JP7303814B2 (pl) |
| KR (1) | KR102956773B1 (pl) |
| CN (1) | CN111601587B (pl) |
| AU (1) | AU2019208396B2 (pl) |
| BR (1) | BR112020014598A2 (pl) |
| CA (1) | CA3088824A1 (pl) |
| ES (1) | ES3009900T3 (pl) |
| FI (1) | FI3740190T3 (pl) |
| HR (1) | HRP20250184T1 (pl) |
| HU (1) | HUE070062T2 (pl) |
| MX (1) | MX2020007656A (pl) |
| PL (1) | PL3740190T3 (pl) |
| PT (1) | PT3740190T (pl) |
| RU (1) | RU2020126518A (pl) |
| SI (1) | SI3740190T1 (pl) |
| WO (1) | WO2019141673A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026092665A1 (en) * | 2024-10-31 | 2026-05-07 | Alar Pharmaceuticals Inc. | Apomorphine salts, their formulations and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1248441A (zh) * | 1998-09-23 | 2000-03-29 | 珠海经济特区生物化学制药厂 | 盐酸阿扑吗啡口含片及其用途 |
| SE0002934D0 (sv) | 2000-08-17 | 2000-08-17 | Axon Biochemicals Bv | New aporphine esters and in their use in therapy |
| JP2004513899A (ja) * | 2000-11-15 | 2004-05-13 | タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド | 抗鬱薬誘発性的機能不全のアポモルヒネによる治療 |
| WO2004082630A2 (en) | 2003-03-17 | 2004-09-30 | Neurohealing Pharmaceuticals, Inc. | High potency dopaminergic treatment of neurological impairment associated with brain injury |
| WO2013183055A1 (en) * | 2012-06-05 | 2013-12-12 | Neuroderm Ltd | Compositions comprising apomorphine and organic acids and uses thereof |
| EP2959904A1 (en) | 2014-06-27 | 2015-12-30 | Institut De Recerca Contra La Leucemia Josep Carreras | Methods for treating, diagnosing and prognosing a haematological malignancy |
| MX2017008382A (es) * | 2014-12-23 | 2018-04-30 | Neuroderm Ltd | Formas cristalinas de apomorfina y sus usos. |
-
2019
- 2019-01-15 PL PL19700411.2T patent/PL3740190T3/pl unknown
- 2019-01-15 CN CN201980008506.8A patent/CN111601587B/zh active Active
- 2019-01-15 BR BR112020014598-0A patent/BR112020014598A2/pt unknown
- 2019-01-15 PT PT197004112T patent/PT3740190T/pt unknown
- 2019-01-15 MX MX2020007656A patent/MX2020007656A/es unknown
- 2019-01-15 US US16/962,585 patent/US11382867B2/en active Active
- 2019-01-15 AU AU2019208396A patent/AU2019208396B2/en active Active
- 2019-01-15 JP JP2020537600A patent/JP7303814B2/ja active Active
- 2019-01-15 SI SI201930891T patent/SI3740190T1/sl unknown
- 2019-01-15 FI FIEP19700411.2T patent/FI3740190T3/fi active
- 2019-01-15 EP EP24213694.3A patent/EP4509187A3/en not_active Withdrawn
- 2019-01-15 RU RU2020126518A patent/RU2020126518A/ru unknown
- 2019-01-15 CA CA3088824A patent/CA3088824A1/en active Pending
- 2019-01-15 WO PCT/EP2019/050922 patent/WO2019141673A1/en not_active Ceased
- 2019-01-15 HU HUE19700411A patent/HUE070062T2/hu unknown
- 2019-01-15 ES ES19700411T patent/ES3009900T3/es active Active
- 2019-01-15 KR KR1020207023131A patent/KR102956773B1/ko active Active
- 2019-01-15 HR HRP20250184TT patent/HRP20250184T1/hr unknown
- 2019-01-15 EP EP19700411.2A patent/EP3740190B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020014598A2 (pt) | 2020-12-08 |
| KR20200110671A (ko) | 2020-09-24 |
| SI3740190T1 (sl) | 2025-03-31 |
| CN111601587B (zh) | 2024-03-05 |
| EP3740190B1 (en) | 2024-11-20 |
| HRP20250184T1 (hr) | 2025-04-11 |
| EP3740190A1 (en) | 2020-11-25 |
| CA3088824A1 (en) | 2019-07-25 |
| FI3740190T3 (fi) | 2025-02-16 |
| JP7303814B2 (ja) | 2023-07-05 |
| US20200405648A1 (en) | 2020-12-31 |
| AU2019208396B2 (en) | 2024-11-14 |
| PT3740190T (pt) | 2025-02-17 |
| AU2019208396A1 (en) | 2020-07-23 |
| EP4509187A2 (en) | 2025-02-19 |
| EP4509187A3 (en) | 2025-03-12 |
| ES3009900T3 (en) | 2025-03-31 |
| CN111601587A (zh) | 2020-08-28 |
| KR102956773B1 (ko) | 2026-04-23 |
| RU2020126518A (ru) | 2022-02-21 |
| HUE070062T2 (hu) | 2025-05-28 |
| JP2021510687A (ja) | 2021-04-30 |
| US11382867B2 (en) | 2022-07-12 |
| MX2020007656A (es) | 2020-09-18 |
| WO2019141673A1 (en) | 2019-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283692A (en) | Novel composition | |
| IL283042A (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| HUE058687T2 (hu) | Azonnali elõkészítés | |
| PL3880654T3 (pl) | Związki 2-formylo-3-hydroksyfenyloksymetylowe zdolne do modulowania hemoglobiny | |
| LT3810602T (lt) | Junginiai | |
| PL3838888T3 (pl) | Triestry kwasu cykloheksanotripropionowego | |
| EP3378505A4 (en) | MATERIAL FOR THE MANUFACTURE OF ARTIFICIAL CRYSTALS | |
| EP3808783A4 (en) | Novel crosslinked alginic acid | |
| EP3473613A4 (en) | SULFONIC ACID ESTER COMPOUND AND USE THEREOF | |
| EP3772265C0 (de) | Hackvorrichtung | |
| IL281720A (en) | Hmgb1 protein derivatives for the removal of biofilms | |
| FIC20260011I1 (fi) | nirogasestaatin dihydrobromidisuolan kiteinen muoto | |
| EP3830103C0 (en) | FLUORINATED BILE ACID DERIVATIVES | |
| IL248594B (en) | Ppar gamma agonists for treatment of multiple sclerosis | |
| HUE065134T2 (hu) | Vegyületek | |
| DK3808747T3 (da) | Imidazopyridinon-forbindelse | |
| LT3867247T (lt) | Naujieji junginiai | |
| IL280448A (en) | Crystalline epinephrine malonate salt | |
| DK3826723T3 (da) | Boronsyrederivater | |
| EP3797648A4 (en) | BEDDING | |
| IL271884B1 (en) | Compounds for the reducing lipotoxic damage | |
| ES1266784Y (es) | Filtro | |
| SI3749673T1 (sl) | Kristalinična oblika biktegravir natrija | |
| HRP20260316T1 (hr) | Postupak akvakulture | |
| EP3743035A4 (en) | MICRO ENCAPSULATED ACID MATERIALS |